|
Video: What is a Stock Split?
|
|
Eterna Therapeutics is a preclinical-stage biopharmaceutical company focusing on realizing the potential of mRNA cell engineering to provide patients with new medicines. Co. has in-licensed a portfolio of over 100 patents covering primary mRNA cell engineering technologies, including technologies for mRNA cell reprogramming, mRNA gene editing, the NoveSlice and UltraSlice gene-editing proteins, and the ToRNAdo mRNA delivery system. Co. has a cell line customization and license agreement with Lineage Cell Therapeutics, Inc. (Lineage), pursuant to which, Lineage may request that Co. develops for, and deliver to, Lineage certain induced pluripotent stem cell lines. According to our ERNA split history records, Eterna Therapeutics has had 1 split. | |
|
Eterna Therapeutics (ERNA) has 1 split in our ERNA split history database. The split for ERNA took place on October 17, 2022. This was a 1 for 20 reverse split, meaning for each 20 shares of ERNA owned pre-split, the shareholder now owned 1 share. For example, a 1000 share position pre-split, became a 50 share position following the split.
When a company such as Eterna Therapeutics conducts a reverse share split, it is usually because shares have fallen to a lower per-share pricepoint than the company would like. This can be important because, for example, certain types of mutual funds might have a limit governing which stocks they may buy, based upon per-share price. The $5 and $10 pricepoints tend to be important in this regard. Stock exchanges also tend to look at per-share price, setting a lower limit for listing eligibility. So when a company does a reverse split, it is looking mathematically at the market capitalization before and after the reverse split takes place, and concluding that if the market capitilization remains stable, the reduced share count should result in a higher price per share.
Looking at the ERNA split history from start to finish, an original position size of 1000 shares would have turned into 50 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Eterna Therapeutics shares, starting with a $10,000 purchase of ERNA, presented on a split-history-adjusted basis factoring in the complete ERNA split history.
Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
04/25/2014 |
|
End date: |
04/23/2024 |
|
Start price/share: |
$12.40 |
|
End price/share: |
$1.96 |
|
Dividends collected/share: |
$0.00 |
|
Total return: |
-84.19% |
|
Average Annual Total Return: |
-16.84% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$1,580.98 |
|
Years: |
10.00 |
|
|
|
Date |
Ratio |
10/17/2022 | 1 for 20 |
|
|